Edition:
India

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

2.15USD
20 Nov 2017
Change (% chg)

$0.08 (+3.61%)
Prev Close
$2.08
Open
$2.10
Day's High
$2.15
Day's Low
$2.10
Volume
106,653
Avg. Vol
257,949
52-wk High
$5.75
52-wk Low
$1.58

Consensus Recommendations

Consensus Recommendation Next Earnings (approx.) Company Fiscal Year
End Month
Last Updated
Outperform -0.22 December 21 Nov 2017

Analyst Recommendations and Revisions

1-5 Linear Scale Current 1 Month
Ago
2 Month
Ago
3 Month
Ago
(1) BUY 0 0 1 1
(2) OUTPERFORM 3 3 3 3
(3) HOLD 2 3 2 2
(4) UNDERPERFORM 0 0 0 0
(5) SELL 0 0 0 0
No Opinion 0 0 0 0
Mean Rating 2.40 2.50 2.17 2.17

Consensus Estimates Analysis

Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
  # of Estimates Mean High Low 1 Year
Ago
SALES (in millions)
Quarter Ending Dec-17 5 3.44 7.80 1.79 2.01
Quarter Ending Mar-18 2 2.76 3.63 1.90 1.50
Year Ending Dec-17 5 10.85 15.00 9.00 7.63
Year Ending Dec-18 5 14.60 30.60 6.90 43.36
Earnings (per share)
Quarter Ending Dec-17 5 -0.22 -0.18 -0.27 -0.24
Quarter Ending Mar-18 2 -0.22 -0.20 -0.24 --
Year Ending Dec-17 5 -1.11 -1.02 -1.17 -1.10
Year Ending Dec-18 5 -1.01 -0.85 -1.13 -0.53

Historical Surprises

Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Estimates vs Actual Estimate Actual Difference Surprise %
SALES (in millions)
Quarter Ending Sep-17 2.22 1.49 0.73 32.88
Quarter Ending Jun-17 2.27 2.66 0.39 17.28
Quarter Ending Mar-17 1.80 3.11 1.30 72.32
Quarter Ending Dec-16 3.71 6.43 2.73 73.53
Quarter Ending Sep-16 2.89 3.37 0.48 16.60

Consensus Estimates Trend

Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
  Current 1 Week
Ago
1 Month
Ago
2 Month
Ago
1 Year
Ago
SALES (in millions)
Quarter Ending Dec-17 3.44 3.65 2.84 2.84 2.01
Quarter Ending Mar-18 2.76 2.76 2.31 3.71 1.50
Year Ending Dec-17 10.85 11.47 10.65 10.65 7.63
Year Ending Dec-18 14.60 14.59 22.09 29.70 43.36

Estimates Revisions Summary

  Last Week Last 4 Weeks
Number Of Revisions: Up Down Up Down
Revenue
Quarter Ending Dec-17 1 1 3 1
Quarter Ending Mar-18 0 0 0 0
Year Ending Dec-17 0 2 2 3
Year Ending Dec-18 1 0 2 1
Earnings